Cinnarizine
Cinnarizine
CLINICAL USE
Vestibular disorders Motion sickness
DOSE IN NORMAL RENAL FUNCTION
Vestibular disorders: 30 mg 3 times a day Motion sickness: 30 mg 2 hours before travel then 15 mg every 8 hours when required
PHARMACOKINETICS
Molecular weight                           :368.5 %Protein binding                           :80 %Excreted unchanged in urine     : <20 Volume of distribution (L/kg)       :No datahalf-life – normal/ESRD (hrs)      :3–6/– DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Unlikely to be dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home